• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Mainz Biomed B.V.

    5/16/22 5:13:28 PM ET
    $MYNZ
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $MYNZ alert in real time by email
    SC 13G 1 ea159714-13ghekland_mainzbio.htm SCHEDULE 13G

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

     

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

    (Amendment No. )*

     

    MAINZ BIOMED N.V.

    (Name of Issuer)

     

    Ordinary Shares, €0.01 par value per share

    (Title of Class of Securities)

     

    N5436L101

    (CUSIP Number)

     

    May 3, 2022

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ☐ Rule 13d-1(b)

     

    ☐ Rule 13d-1(c)

     

    ☒ Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

    CUSIP No.

     

    1 

    NAMES OF REPORTING PERSONS

    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

    Hans Hekland

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

     

    (a) ☐

    (b) ☐

    3 SEC USE ONLY

     

     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Germany

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH:

    5 SOLE VOTING POWER

     

    821,427

    6 SHARED VOTING POWER

     

    0

    7 SOLE DISPOSITIVE POWER

     

    821,427

    8 SHARED DISPOSITIVE POWER

     

    0

    9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    821,427 Ordinary Shares

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) ☐

     

    11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

    5.9%

    12 TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    IN

     

    2

     

     

    Item 1(a). Name of Issuer:

     

    Mainz BioMed N.V. (the “Issuer”)

     

    Item 1(b). Address of Issuer’s Principal Executive Offices:

     

    Robert Koch Strasse 50, 55129 Mainz, Germany

     

    Item 2(a). Names of Persons Filing:

     

    The names of the persons filing this report (collectively, the “Reporting Persons”) are:

     

    Hans Hekland

     

    Item 2(b). Address of Principal Business Office or, if None, Residence:

     

    The address of the principal business office of each of the Reporting Persons is:

     

    Robert Koch Strasse 50, 55129 Mainz, Germany 

     

    Item 2(c). Citizenship:

     

    Germany

     

    Item 2(d). Title of Class of Securities:

     

    Ordinary Shares, par value €0.01 per share (“Ordinary Shares”)

     

    Item 2(e). CUSIP Number:

     

    N5436L101

     

    Item 3. If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     

    Not applicable.

     

    3

     

     

    Item 4. Ownership.

     

    (a) Amount beneficially owned: 821,427 Ordinary Shares

     

    (b) Percent of class: 5.9%

     

    (c) Number of shares as to which the person has

     

    (i)Sole power to vote or to direct the vote 821,427 Ordinary Shares

     

    (ii)Shared power to vote or to direct the vote 0 Ordinary Shares

     

    (iii)Sole power to dispose or to direct the disposition of 821,427 Ordinary Shares

     

    (iv)Shared power to dispose or to direct the disposition of 0 Ordinary Shares

     

    Hans Hekland has sole voting and dispositive power over Ordinary Shares held by ColoAlertAS

     

    Item 5. Ownership of Five Percent or Less of a Class.

     

    If this statement is being filed to report the fact that as of the date hereof the Reporting Persons have ceased to be the beneficial owner of more than five percent of the class of securities, check the following ☐.

     

    Item 6. Ownership of More than Five Percent on Behalf of Another Person.

     

    Not applicable.

     

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

     

    Not applicable.

     

    Item 8. Identification and Classification of Members of the Group.

     

    Not applicable.

     

    Item 9. Notice of Dissolution of Group.

     

    Not applicable.

     

    Item 10. Certification.

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

     

    4

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of its knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

     

    Date: May 16, 2022

     

    Hans Hekland

     

    By: /s/ Hans Hekland  
    Name:  Hans Hekland  

     

     

    5

     

     

    Get the next $MYNZ alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $MYNZ

    DatePrice TargetRatingAnalyst
    2/14/2025$14.00Buy
    Maxim Group
    11/25/2024Buy → Neutral
    H.C. Wainwright
    11/21/2023Overweight → Neutral
    Cantor Fitzgerald
    6/21/2022$25.00Buy
    H.C. Wainwright
    More analyst ratings

    $MYNZ
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Mainz Biomed Announces Pricing of $4.0 Million Follow-On Offering of Ordinary Shares and Warrants

      BERKELEY, Calif. and MAINZ, Germany, May 19, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) ("Mainz Biomed" or the "Company"), a molecular genetics diagnostic company specializing in the early detection of cancer, today announced the pricing of a follow-on offering of 2,000,000 units, with each unit consisting of one ordinary share (or pre-funded warrant in lieu thereof), one Series A warrant to purchase one ordinary share, and one Series B warrant to purchase one ordinary share for gross proceeds of approximately $4.0 million. Each unit is being sold at an effective offering price of $2.00 per unit. Each Series A warrant will be immediately exercisable at an exercise price of $2

      5/19/25 8:01:15 PM ET
      $MYNZ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Mainz Biomed Announces Interim Read Out For Its eAArly DETECT 2 Clinical Study

      Company intends to provide an interim read out by the end of summer 2025 Top-line results anticipated in Q4 2025; study on track to support U.S. pivotal trial initiation in 2026 BERKELEY, Calif. and MAINZ, Germany, May 16, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) ("Mainz Biomed" or the "Company"), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today that it intends to provide an interim read out of its eAArly DETECT 2 feasibility study by the end of summer 2025. The study is evaluating the Company's next-generation colorectal cancer (CRC) screening test that integrates Mainz Biomeds proprietary mRNA biomarkers, an AI-devel

      5/16/25 8:01:00 AM ET
      $MYNZ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Mainz Biomed Enters into Technology Partnership with EDX Medical Group

      BERKELEY, Calif. and MAINZ, Germany, April 29, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) ("Mainz Biomed" or the "Company"), a molecular genetics diagnostic company specializing in the early detection of cancer, has entered into a technology partnership with UK-based EDX Medical Group plc (AQSE: EDX), which develops innovative digital diagnostic products and services supporting personalized treatments for cancer, cardiovascular and infectious diseases. Under the agreement, EDX Medical will access Mainz Biomed's molecular diagnostic technology as part of the expansion of its portfolio of products for sale in the UK. "We are delighted to join forces with EDX Medical Limited t

      4/29/25 8:01:00 AM ET
      $MYNZ
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MYNZ
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Maxim Group initiated coverage on Mainz Biomed B.V. with a new price target

      Maxim Group initiated coverage of Mainz Biomed B.V. with a rating of Buy and set a new price target of $14.00

      2/14/25 8:10:14 AM ET
      $MYNZ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Mainz Biomed B.V. downgraded by H.C. Wainwright

      H.C. Wainwright downgraded Mainz Biomed B.V. from Buy to Neutral

      11/25/24 7:48:30 AM ET
      $MYNZ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Mainz Biomed B.V. downgraded by Cantor Fitzgerald

      Cantor Fitzgerald downgraded Mainz Biomed B.V. from Overweight to Neutral

      11/21/23 7:33:52 AM ET
      $MYNZ
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MYNZ
    Financials

    Live finance-specific insights

    See more
    • Mainz Biomed Acquires Entire Intellectual Property Portfolio for its Colorectal Cancer Diagnostic Test Program

      Transaction entails executing option agreements to purchase IP portfolio associated with current ColoAlert product and the novel gene expression (mRNA) biomarkers being evaluated in ColoFuture/eAARLY DETECT Studies BERKELEY, Calif. and MAINZ, Germany, Feb. 21, 2023 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) ("Mainz Biomed" or the "Company"), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today the execution of its option from Uni Targeting Research AS to acquire all of the previously licensed scientific intellectual property ("IP") for its flagship product ColoAlert, a highly efficacious, and easy-to-use detection test for colorec

      2/21/23 3:01:00 AM ET
      $MYNZ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Mainz Biomed Acquires Exclusive Rights to Novel mRNA Biomarkers

      Potential for ColoAlert to Emerge as the Most Robust and Accurate At-home Screening Test for Colorectal Cancer Biomarkers Demonstrated Unique Ability to Identify Curable Precancerous Colonic Polyps as well as Curable Early-Stage Colorectal Cancer BERKELEY, Calif. and MAINZ, Germany, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) ("Mainz Biomed" or the "Company"), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today it has entered into a Technology Rights Agreement with Socpra Sciences Santé Et Humaines S.E.C. ("TTS") to access a portfolio of novel mRNA biomarkers for potential future integration into ColoAlert,

      1/5/22 3:01:00 AM ET
      $MYNZ
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MYNZ
    SEC Filings

    See more
    • SEC Form 424B3 filed by Mainz Biomed N.V.

      424B3 - MAINZ BIOMED N.V. (0001874252) (Filer)

      5/21/25 6:49:54 AM ET
      $MYNZ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by Mainz Biomed N.V.

      6-K - MAINZ BIOMED N.V. (0001874252) (Filer)

      5/21/25 6:47:10 AM ET
      $MYNZ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by Mainz Biomed N.V.

      EFFECT - MAINZ BIOMED N.V. (0001874252) (Filer)

      5/19/25 12:15:25 AM ET
      $MYNZ
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MYNZ
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Mainz Biomed N.V.

      SC 13G/A - MAINZ BIOMED N.V. (0001874252) (Subject)

      10/7/24 4:47:27 PM ET
      $MYNZ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Mainz Biomed N.V. (Amendment)

      SC 13G/A - MAINZ BIOMED N.V. (0001874252) (Subject)

      2/13/24 2:39:04 PM ET
      $MYNZ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Mainz Biomed N.V.

      SC 13G - MAINZ BIOMED N.V. (0001874252) (Subject)

      3/1/23 6:38:43 AM ET
      $MYNZ
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MYNZ
    Leadership Updates

    Live Leadership Updates

    See more
    • Mainz Biomed Enters into Technology Partnership with EDX Medical Group

      BERKELEY, Calif. and MAINZ, Germany, April 29, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) ("Mainz Biomed" or the "Company"), a molecular genetics diagnostic company specializing in the early detection of cancer, has entered into a technology partnership with UK-based EDX Medical Group plc (AQSE: EDX), which develops innovative digital diagnostic products and services supporting personalized treatments for cancer, cardiovascular and infectious diseases. Under the agreement, EDX Medical will access Mainz Biomed's molecular diagnostic technology as part of the expansion of its portfolio of products for sale in the UK. "We are delighted to join forces with EDX Medical Limited t

      4/29/25 8:01:00 AM ET
      $MYNZ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Mainz Biomed Announces Petra Smeltzer Starke to Join Company as Brand Ambassador

      BERKELEY, Calif. and MAINZ, Germany, Sept. 18, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) ("Mainz Biomed" or the "Company"), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today the addition of Petra Smeltzer Starke as a Brand Ambassador for the Company. As Brand Ambassador she will help the Company in the development and dissemination of messaging focused on the importance of early detection of colorectal cancer. "We are excited about Petra joining our team as Brand Ambassador. Her broad and deep experience will be invaluable to us as we bring our next generation colorectal cancer screening product to market, with the

      9/18/24 8:01:00 AM ET
      $MYNZ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Mainz Biomed Appoints Tarrin Khairi-Taraki as VP of Commercial Operations

      Former Natera Manager will oversee all aspects of sales and support in EMEA, ensuring the continued commercialization of ColoAlert® across the region BERKELEY, Calif. and MAINZ, Germany, Oct. 26, 2023 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) ("Mainz Biomed" or the "Company"), a molecular genetics diagnostic company specializing in the early detection of cancer, is proud to announce the appointment of Tarrin Khairi-Taraki as Vice President of Commercial Operations, EMEA. Tarrin will play a pivotal role in steering Mainz Biomed's continued success, focusing on the commercialization of its flagship product, ColoAlert® — a highly effective and user-friendly at-home detection test f

      10/26/23 8:01:00 AM ET
      $MYNZ
      Biotechnology: Pharmaceutical Preparations
      Health Care